Piramal Pharma Q4 Results: Net profit slides 75% YoY to Rs 50 crore
On like-to-like financials, the CDMO business that contributes 57% of revenues, declined 8% YoY to Rs 2164 crore. The complex hospital generics business grew 28% due to strong demand for the inhalation anesthesia portfolio. The consumer health business sales rose 5% to Rs 206 crores driven by sustained marketing and brand building efforts
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
